Evidence map›Paper›PMID 40047907›Full record

ArticleEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2025

Soluble urokinase plasminogen activator receptor biomarker is not a predictor of mortality in high-risk hip fracture patients.

Konstantinos Avgerinos, Spyridon Katsanos, Pavlos Altsitzioglou, Alexandros Zikopoulos, Anastasios Roustemis, Orestis Konstantas, Ioannis Zafeiris, Fotini Soucacos, Dimitrios Serenidis, Dimitrios Mastrokalos and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Konstantinos AvgerinosNational and Kapodistrian University of Athens, Athens, Greece.
Spyridon KatsanosNational and Kapodistrian University of Athens, Athens, Greece.
Pavlos AltsitzioglouNational and Kapodistrian University of Athens, Athens, Greece.
Alexandros ZikopoulosNational and Kapodistrian University of Athens, Athens, Greece.
Anastasios RoustemisNational and Kapodistrian University of Athens, Athens, Greece.
Orestis KonstantasNational and Kapodistrian University of Athens, Athens, Greece.
Ioannis ZafeirisNational and Kapodistrian University of Athens, Athens, Greece.
Fotini SoucacosNational and Kapodistrian University of Athens, Athens, Greece.
Dimitrios SerenidisNational and Kapodistrian University of Athens, Athens, Greece.
Dimitrios MastrokalosNational and Kapodistrian University of Athens, Athens, Greece.
Dimitrios KoulalisNational and Kapodistrian University of Athens, Athens, Greece.
Andreas MavrogenisNational and Kapodistrian University of Athens, Athens, Greece. afm@otenet.gr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe soluble urokinase plasminogen activator receptor (SuPAR) is a biomarker of inflammation and immune activation that has been related with mortality in a vast spectrum of diseases in the elderly. Its prognostic value in preoperative evaluation for non-cardiac surgery has been promising. However, up to date there are no studies in high-risk patients undergoing hip fracture surgery. Therefore, we performed this prospective study aims to evaluate the prognostic value of SuPAR and other common clinical, echocardiographic, and blood biomarkers for the 1-year survival of high-risk hip fracture surgery patients.

methodsWe studied 46 patients with hip fracture that underwent hip fracture surgery from 2019 to 2024. There were 10 men and 36 women, over 65 years of age (mean, 85 ± 8 years) with at least one high-risk characteristic (dementia, chronic immobilization, age > 90 years). Upon admission, complete clinical and laboratory assessments, including electrocardiogram and cardiac ultrasonography, radiographs, and blood sampling, were conducted. Serum blood levels of SuPAR as well as natriuretic peptides and troponin I were measured. The Katz index of frailty was calculated. The patients were followed for 1 year after admission and hip fracture surgery. At that time, the patients or their relatives were contacted through telephone, and their 1-year survival was documented.

resultsOverall, 25 (54.3%) patients were dead at 1-year examination. There was no significant difference in baseline values of SuPAR between patients dead or alive at follow-up (6.30 ng/dl [range, 4.95-7.05 ng/dl] vs. 6.25 ng/dl [4.25-9.05 ng/dl], respectively; p value = 0.767), and SuPAR has not been related to 1-year mortality (HR 0.802; 95% CI 0.248-2.595; p value = 0.712). The only univariate and multivariate predictors of survival were age (HR 1.098; 95% CI 1.003-1.181; p = 0.041) and Katz index ≤ 4 (HR 4.490; 95% CI 1.180-17.093; p = 0.028).

conclusionThis study showed that SuPAR is not a predictive factor for 1-year mortality in high-risk patients undergoing hip fracture surgery. Older age and Katz index score ≤ 4 were the only independent predictors of 1-year mortality. Therefore, although no definite conclusion can be drawn from such a small number of patients, no trend in mortality for this measurement has been observed, suggesting SuPAR and similar biomarkers should not be considered in the evaluation of mortality in high-risk hip fracture patients.

Indexed as

Hip FracturesReceptors, Urokinase Plasminogen ActivatorAgedAged, 80 and overBiomarkersFemaleHumansMalePredictive Value of TestsPrognosisProspective StudiesRisk FactorsTroponin IBiomarkersPLAUR protein, humanReceptors, Urokinase Plasminogen ActivatorTroponin IBiomarkerFrailtyHip fracturesKatz indexMortalitySuPAR

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.